



(51) International Patent Classification:

C07D 417/12 (2006.01) **A61K 31/427** (2006.01)
C07D 401/12 (2006.01) **A61P 35/00** (2006.01)
C07D 207/325 (2006.01)

(21) International Application Number:

PCT/US2012/039468

(22) International Filing Date:

24 May 2012 (24.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/491,076 27 May 2011 (27.05.2011) US

(71) Applicant (for all designated States except US): **AMBRX, INC.** [US/US]; 10975 N. Torrey Pines Road, Suite 100, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MIAO, Zhenwei** [US/US]; 15887 Sunnyfield Place, San Diego, CA 92127 (US). **ATKINSON, Kyle, C.** [US/US]; 2024 Golden Vue Drive, Golden, CO 80401 (US). **BIROC, Sandra**

[US/US]; 1036 Camellia Drive, Alameda, CA 94502 (US). **BUSS, Timothy** [US/US]; 1745 Catalpa Road, Carlsbad, CA 92011 (US). **COOK, Melissa** [US/US]; 976 S. Mollison Avenue, Apt. 5, El Cajon, CA 92020 (US). **KRAYNOV, Vadim** [US/US]; 5457 White Oak Lane, San Diego, CA 92130 (US). **MARSDEN, Robin** [US/US]; 6358 Budlong Lake Avenue, San Diego, CA 92119 (US). **PINKSTAFF, Jason** [US/US]; 2095 Wandering Road, Encinitas, CA 92024 (US). **SKIDMORE, Lillian** [US/US]; 6232 Canyon Bluff Court, San Diego, CA 92121 (US). **SUN, Ying** [CN/US]; 14972 Avenida Venusto #65, San Diego, CA 92128 (US). **SZYDLIK, Agnieszka** [US/US]; 3050 Rue D'orleans #283, San Diego, CA 92110 (US). **VALENTA, Ianina** [VE/US]; 13442 Sebago Avenue, Roway, CA 92064 (US).

(74) Agent: **POULOS, Sabrina, D.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,

[Continued on next page]

(54) Title: COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES




FIG. 4

(57) Abstract: [00420] Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.



KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))